Generex Oral-lyn, Generex’s proprietary oral insulin spray product, is the first non-injectable insulin to be approved in the country.
The spray is delivered via the company’s proprietary RapidMist device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn does not reach the lungs.
Lebanese Ministry of Public Health has approved for the importation, marketing and sale of this drug under the company’s sub-licensee Benta s.a.l, aimed for the treatment of patients with Type-1 and Type-2 diabetes.
Anna Gluskin, Chairman & CEO of Generex, said: “It is with great enthusiasm that we launch Generex Oral-lyn in Lebanon alongside Benta s.a.l., known for their leading edge innovation.”
